The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.
 
Mark Yarchoan
Consulting or Advisory Role - Eisai; Exelixis; Geneos
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
 
Edward Gane
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen
Speakers' Bureau - Abbvie; Gilead Sciences
Research Funding - Abbvie; Gilead Sciences; Janssen; Lilly; Merck; SillaJen
 
Thomas Urban Marron
Consulting or Advisory Role - AstraZeneca; Atara Biotherapeutics; Boehringer Ingelheim; Genentech; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Atara Biotherapeutics (Inst); Genentech
 
Sarah Rochestie
Employment - Geneos
 
Neil Cooch
Employment - Geneos
Stock and Other Ownership Interests - Geneos
Travel, Accommodations, Expenses - Geneos
 
Joann Peters
No Relationships to Disclose
 
Ildiko Csiki
Employment - Sensei Biotherapeutics
Consulting or Advisory Role - Geneos; Sensei Biotherapeutics
 
Alfredo Perales-Puchalt
Employment - Geneos; Inovio Pharmaceuticals
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Globus; IgM Biosciences; Merck; Pfizer; Vanda Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Methods and compositions for treating cancer - WO2016054153A1 Optimized Synthetic Consensus Immunogenic Compositions Targeting the Follicle Stimulating Hormone Receptor (FSHR) - WO2018044929A1 (Inst)
 
Niranjan Sardesai
Employment - BMS (I); Geneos; Merck (I)
Leadership - Geneos
Stock and Other Ownership Interests - BMS (I); Geneos; Inovio Pharmaceuticals; Merck (I)
Patents, Royalties, Other Intellectual Property - I am an inventor on several patents assigned to my current and former employers Geneos Therapeutics and Inovio Pharmaceuticals respectively. As these are assigned to the company I receive no royalties or will receive no royalties on these patents.